Pharmaceutical

Bristol Myers Squibb reports dip in net income for Q2 2024

Bristol Myers Squibb (BMS) has posted net income attributable to the company of $1.7bn during Q2 2024, a 19% drop versus $2.1bn in Q2 2023.

Jul 30, 2024 - 04:00
Bristol Myers Squibb reports dip in net income for Q2 2024
Bristol Myers Squibb (BMS) has posted net income attributable to the company of $1.7bn during Q2 2024, a 19% drop versus $2.1bn in Q2 2023.
Read the original article

Tags:

Previous Article

FDA approves Luye Pharma’s ERZOFRI for schizophrenia

Next Article

CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Study: Giving an antibiotic to household contacts of people with leprosy slashes chances of spread

Study: Giving an antibiotic to household contacts of pe...

May 17, 2023

STAT+: As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm

STAT+: As AI promises to revolutionize medical note-tak...

Mar 28, 2023

STAT+: Federal Medicaid officials cajole states to auto-enroll beneficiaries as huge coverage losses loom

STAT+: Federal Medicaid officials cajole states to auto...

Mar 19, 2023